HOFFMAN ESTATES, Ill. & LOS ANGELES--(BUSINESS WIRE)--Siemens Medical Solutions announced today that it will begin clinical trials under an investigational new drug (IND) application submitted to the Food and Drug Administration (FDA) for a breakthrough imaging biomarker that could potentially identify Alzheimer’s disease prior to the onset of noticeable symptoms.